Recovery of the Immune System in a New Study with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
A new scientific study points to a natural way for improving the immune system. According to an article published in the journal Acta Oncologica, treatment with the natural antiviral supplement Gene-Eden returned the number of immune cells to normal levels in a pancreatic cancer patient with a weak immune system. The study was conducted at the Center for the Biology of Chronic Disease by Hanan Polansky and Ido Dafni. Acta Oncologica is a leading scientific journal in clinical oncology and related disciplines, and the official journal of the five Nordic oncological societies.
Pancreatic cancer is a devastating disease. Almost no one recovers from it. In United States alone, physicians diagnose more than 40,000 new cases of pancreatic cancer each year, and more than 35,000 die from it annually. The known treatments are mostly ineffective. Although doctors try surgical removal of the tumor (for a localized tumor), chemotherapy, and radiation therapy, less than 5 out of a 100 patients are still alive 5 years from diagnosis.
In this study, the patient was a 61 years old female with an inoperable pancreatic tumor. First, the patient received two months of a certain type of chemotherapy, which had no effect on the tumor’s growth. In addition, the chemotherapy almost destroyed the patient’s immune system. Blood tests showed that there were almost no immune cells left in the patient’s body. Since the first type of chemotherapy failed, the doctors replaced it with a different type of chemotherapy. The problem with the second chemotherapy was that it was supposed to help in coping with the symptoms, but not shrink the tumor. In addition, the patient was given the antiviral supplement Gene-Eden. Five weeks later, to the great surprise of the doctors, a CT scan and some blood tests showed a 34% decrease in the tumor size, and an increase in the number of immune cells back to normal levels!
Gene-Eden, the natural antiviral dietary supplement, targets many chronic viruses. The development of Gene-Eden was inspired by Hanan Polansky’s discovery of the Starved Gene phenomenon. According to Dr. Polansky, many common viruses, including the Hepatitis Virus (Hep B virus, Hep C virus, HBV, HCV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), and Epstein Barr Virus (EBV), to name a few, are genetic parasites. These viruses enter the cell and plant themselves in the nucleus. Then, they start to “steal” resource they find in the nucleus from their neighboring human genes. Without the missing resources, the starved human genes produce less of their proteins, including the Retinoblastoma (Rb) and BRCA1 proteins. Since the missing human proteins are needed for controlling the rate of cell replication, the result is too much cell replication and the development of tumors.
If you are interested in reading more about the Starved Gene discovery, you can find a detailed explanation, specifically formulated for the general public, at http://www.gene-eden.com/Gene-Eden.htm.
The Starved Gene discovery teaches us that chronic viruses can cause many major diseases, including pancreatic cancer. It also shows us that an antiviral treatment against chronic viruses should be effective in treating these diseases. According to the authors, the results of this study confirm the discovery. They show that that by targeting the chronic viruses in the patient’s body, Gene-Eden can improve the patient’s condition, to the great surprise of those unfamiliar with Dr. Polansky’s discovery.
Study: “Gene-Eden, a broad range, natural antiviral supplement, may shrink tumors and strengthen the immune system” Hanan Polansky, Ido Dafni. Acta Oncologica; Posted online on 8 Jan 2010.
For more information on Gene-Eden, visit the Gene-Eden website. Gene-Eden is available on Amazon.com.
Did you enjoy this post? Why not leave a comment below and continue the conversation, or subscribe to my feed and get articles like this delivered automatically to your feed reader.
Comments
No comments yet.
Leave a comment